Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H25NO5S |
Molecular Weight | 415.503 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C23)=C1
InChI
InChIKey=CMEGANPVAXDBPL-INIZCTEOSA-N
InChI=1S/C22H25NO5S/c1-12(24)23-16-8-6-13-10-18(26-2)21(27-3)22(28-4)20(13)14-7-9-19(29-5)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/9474240 | https://www.ncbi.nlm.nih.gov/pubmed/2191947Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15588720
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9474240 | https://www.ncbi.nlm.nih.gov/pubmed/2191947
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15588720
Thiocolchicine is a colchicine-derivative used in the therapy of some diseases and extensively studied in the field of oncological research as antimitotic agent. It is tubulin polymerization and microtubule assembly inhibitor and axonal cytoskeleton modulator; apoptosis inducer. Thiocolchicine-dimers were shown to be potent topoisomerase I inhibitors. Thiocolchicine is a potential antitumor agent.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
0.65 µM [IC50] | |||
Target ID: CHEMBL1781 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15588720 |
5.2 µM [IC50] | ||
Target ID: CHEMBL400 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10602712 |
0.6 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24893912
for the treatment of Peyronie's Disease: 2mL injection containing 4mg of thiocolchicine, injected using a 0.3x8mm needle in many punctures into the plaque. Thiocolchicine 4mg or verapamil 5mg were given in 7 injections (once a week)
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9474240
At concentrations from 1 nM to 100 uM, Thiocolchicine inhibited cancer cell proliferation
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67421
Created by
admin on Sat Dec 16 08:16:35 GMT 2023 , Edited by admin on Sat Dec 16 08:16:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
17648
Created by
admin on Sat Dec 16 08:16:35 GMT 2023 , Edited by admin on Sat Dec 16 08:16:35 GMT 2023
|
PRIMARY | |||
|
C1252
Created by
admin on Sat Dec 16 08:16:35 GMT 2023 , Edited by admin on Sat Dec 16 08:16:35 GMT 2023
|
PRIMARY | |||
|
m10747
Created by
admin on Sat Dec 16 08:16:35 GMT 2023 , Edited by admin on Sat Dec 16 08:16:35 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID90181751
Created by
admin on Sat Dec 16 08:16:35 GMT 2023 , Edited by admin on Sat Dec 16 08:16:35 GMT 2023
|
PRIMARY | |||
|
47541468FI
Created by
admin on Sat Dec 16 08:16:35 GMT 2023 , Edited by admin on Sat Dec 16 08:16:35 GMT 2023
|
PRIMARY | |||
|
220-346-8
Created by
admin on Sat Dec 16 08:16:35 GMT 2023 , Edited by admin on Sat Dec 16 08:16:35 GMT 2023
|
PRIMARY | |||
|
2730-71-4
Created by
admin on Sat Dec 16 08:16:35 GMT 2023 , Edited by admin on Sat Dec 16 08:16:35 GMT 2023
|
PRIMARY | |||
|
186301
Created by
admin on Sat Dec 16 08:16:35 GMT 2023 , Edited by admin on Sat Dec 16 08:16:35 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD